Dupilumab for Allergic Contact Dermatitis

Phase-Based Progress Estimates
Allergic Contact DermatitisDupilumab - Drug
All Sexes
What conditions do you have?

Study Summary

This trial will test whether the drug dupilumab can help improve symptoms in people with allergic contact dermatitis.

Eligible Conditions
  • Allergic Contact Dermatitis

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: week 0, week0+72-120 hours, week 12 and week 12+72-120 hours

Week 12
Change in Body Surface Area (BSA)
Change in Dermatology Life Quality Index (DLQI)
Change in Eczema Area and Severity Index (EASI) score
Change in Investigator's Global Assessment (IGA) score
Change in Numerical Rating Scale (NRS) itch
Change in SLEEPY-Q (Sleep Questionnaire) score
Week 12
Blood Samples
Week 12
Skin Samples

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Side Effects for

OLE Period: Dupilumab/Dupilumab
12%Accidental Overdose
2%Dermatitis Atopic
1%Multiple Fractures
This histogram enumerates side effects from a completed 2021 Phase 4 trial (NCT04033367) in the OLE Period: Dupilumab/Dupilumab ARM group. Side effects include: Accidental Overdose with 12%, Conjunctivitis with 2%, Nasopharyngitis with 2%, Headache with 2%, Dermatitis Atopic with 2%.

Trial Design

1 Treatment Group

Subjects with Allergic Contact Dermatitis
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Dupilumab · No Placebo Group · Phase 4

Subjects with Allergic Contact Dermatitis
Experimental Group · 1 Intervention: Dupilumab · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: week 0, week0+72-120 hours, week 12 and week 12+72-120 hours

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor
1,481 Previous Clinical Trials
9,735,781 Total Patients Enrolled
Regeneron PharmaceuticalsIndustry Sponsor
549 Previous Clinical Trials
200,394 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The participant must have a contact allergen that results in a strong or extreme reaction upon patch testing within 6 months of the baseline visit, and this reaction can be duplicated at the initiation of the study.
The patient has not had success with topical medications or allergen avoidance in the past 6 months.
The subject is able and willing to provide informed consent, participate in study visits, and undergo visit procedures.
You are at least 18 years old.
indicates An investigator's global assessment score of at least 3, indicates that the subject has moderate to severe psoriasis.
Allergic contact dermatitis is diagnosed by principles investigators who are experts in the field